Risk/Benefit Of Asthma Drugs To Be Debated At Future Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA awaits data from controlled trials of seven long-acting beta agonists before bringing them back for panel review later this year.